119 results
Page 5 of 6
8-K
EX-1.1
0nm4cna 1ofgztaor
20 May 19
Entry into a Material Definitive Agreement
9:28am
424B5
nsbil
20 May 19
Prospectus supplement for primary offering
9:18am
8-K
EX-99.1
7muux3eq
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.2
jowguhuk2axtecq quv
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
az5sj guw
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
EX-99.1
jxvhc96sh4 mj
7 May 19
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
8:17am
DEF 14A
235bkj13 e9zysn
1 Apr 19
Definitive proxy
5:20pm
8-K
EX-99.1
n7d4xgc1a
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
EX-99.1
5xk41c5ykwof0vf0 4n
25 Mar 19
Other Events
4:45pm
S-3
11lpg
14 Mar 19
Shelf registration
4:45pm
8-K
EX-99.1
eiia9hhm do
12 Mar 19
Other Events
5:21pm
10-K
3adkhs68109n g13
12 Mar 19
Annual report
12:00am
8-K
EX-99.1
owtf3
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm
8-K
EX-99.1
9ui8tqn
7 Mar 19
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
4:42pm
8-K
EX-99.1
fu8uxs0kx a4
4 Mar 19
Other Events
4:19pm
8-K
EX-99.1
krolq6aswmk
11 Feb 19
Regulation FD Disclosure
4:47pm
8-K
EX-99.1
rmug6g8d4rw852tdy
4 Feb 19
Other Events
5:03pm
8-K
EX-99.1
oroo46fk
3 Jan 19
Regulation FD Disclosure
4:16pm